Answers are grounded in this paper and cite their sources.
In the present study, thiophene incorporated schiff base (1B) and phenylborosiloxane (2B) were synthesized by the refluxing method. The structure of the synthesized compounds 1B and 2B were characterized by using spectroscopic techniques such as: 1H NMR, 13C NMR, 11B NMR and FTIR. Also, thermal analysis performed for the phenylborosiloxane (2B). In silico Molecular docking, ADMET profiling, drug-likeness evaluation, and PASS prediction analyses were carried out to predict the potential biological relevance for future experimental investigation. Molecular docking was performed against the BRAF and TGF-β receptor type I proteins (PDB IDs: 6V34 and 5E8T), revealing moderate binding affinities through conventional hydrogen bonding interactions, with docking scores ranging from −5.3 to −7.1 kcal/mol. Furthermore, molecular docking also performed with the known inhibitor of proteins i.e Vemurafenib and Galunisertib taking them as control for the comparative study. Both compounds exhibited promising ADMET characteristics and satisfied key drug-likeness criteria. Additionally, PASS prediction indicated promising Pa values for Complement factor D inhibitor, Monodehydroascorbate reductase (NADH) inhibitor, Peptidyltransferase inhibitor and Chemosensitizer. These findings suggest that 1B and 2B own significant potential as lead contenders for further in vitro biological evaluation and therapeutic development.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: